Zum Hauptinhalt springen
UB Hagen

Coenzyme Q10 Improves Lipid Metabolism and Ameliorates Obesity by Regulating CaMKII-Mediated PDE4 Inhibition.

Xu, Z ; Huo, J ; et al.
In: Scientific reports, Jg. 7 (2017-08-15), Heft 1, S. 8253
Online academicJournal
Zugriff:
Full Text Finder (Volltext)

Our recent studies revealed that supplementation with the reduced form of coenzyme Q10 (CoQ 10 H 2 ) inhibits oxidative stress and slows the process of aging in senescence-accelerated mice. CoQ 10 H 2 inhibits adipocyte differentiation and regulates lipid metabolism. In the present study, we show that dietary supplementation with CoQ 10 H 2 significantly reduced white adipose tissue content and improved the function of brown adipose tissue by regulating expression of lipid metabolism-related factors in KKAy mice, a model of obesity and type 2 diabetes. In the liver, CoQ 10 H 2 reduced cytoplasmic Ca 2+ levels and consequently inhibited the phosphorylation of CaMKII. CoQ 10 H 2 also regulated the activity of the transcription factor C-FOS and inhibited gene expression of PDE4, a cAMP-degrading enzyme, via the CaMKII-MEK1/2-ERK1/2 signaling pathway, thereby increasing intracellular cAMP. This increased cAMP activated AMPK, enhanced oxidative decomposition of lipids, and inhibited de novo synthesis of fatty acids, inhibiting the development and progression of obesity and type 2 diabetes. These results suggest that CoQ 10 H 2 supplementation may be useful as a treatment for metabolic disorders associated with obesity.

Titel:
Coenzyme Q10 Improves Lipid Metabolism and Ameliorates Obesity by Regulating CaMKII-Mediated PDE4 Inhibition.
Autor/in / Beteiligte Person: Xu, Z ; Huo, J ; Ding, X ; Yang, M ; Li, L ; Dai, J ; Hosoe, K ; Kubo, H ; Mori, M ; Higuchi, K ; Sawashita, J
Link:
Zeitschrift: Scientific reports, Jg. 7 (2017-08-15), Heft 1, S. 8253
Veröffentlichung: London : Nature Publishing Group, copyright 2011-, 2017
Medientyp: academicJournal
ISSN: 2045-2322 (electronic)
DOI: 10.1038/s41598-017-08899-7
Schlagwort:
  • Adipocytes drug effects
  • Adipocytes metabolism
  • Adipose Tissue, Brown drug effects
  • Adipose Tissue, Brown metabolism
  • Animals
  • Body Weight drug effects
  • Calcium Signaling drug effects
  • Disease Models, Animal
  • Gene Expression Regulation drug effects
  • Insulin Resistance
  • Liver drug effects
  • Liver metabolism
  • Metabolic Syndrome drug therapy
  • Metabolic Syndrome metabolism
  • Mice
  • Obesity drug therapy
  • Obesity genetics
  • Phosphodiesterase 4 Inhibitors pharmacology
  • Sarcoplasmic Reticulum Calcium-Transporting ATPases genetics
  • Sarcoplasmic Reticulum Calcium-Transporting ATPases metabolism
  • Ubiquinone metabolism
  • Ubiquinone pharmacology
  • Calcium-Calmodulin-Dependent Protein Kinase Type 2 metabolism
  • Cyclic Nucleotide Phosphodiesterases, Type 4 metabolism
  • Lipid Metabolism drug effects
  • Obesity metabolism
  • Ubiquinone analogs & derivatives
Sonstiges:
  • Nachgewiesen in: MEDLINE
  • Sprachen: English
  • Publication Type: Journal Article
  • Language: English
  • [Sci Rep] 2017 Aug 15; Vol. 7 (1), pp. 8253. <i>Date of Electronic Publication: </i>2017 Aug 15.
  • MeSH Terms: Lipid Metabolism* / drug effects ; Calcium-Calmodulin-Dependent Protein Kinase Type 2 / *metabolism ; Cyclic Nucleotide Phosphodiesterases, Type 4 / *metabolism ; Obesity / *metabolism ; Ubiquinone / *analogs & derivatives ; Adipocytes / drug effects ; Adipocytes / metabolism ; Adipose Tissue, Brown / drug effects ; Adipose Tissue, Brown / metabolism ; Animals ; Body Weight / drug effects ; Calcium Signaling / drug effects ; Disease Models, Animal ; Gene Expression Regulation / drug effects ; Insulin Resistance ; Liver / drug effects ; Liver / metabolism ; Metabolic Syndrome / drug therapy ; Metabolic Syndrome / metabolism ; Mice ; Obesity / drug therapy ; Obesity / genetics ; Phosphodiesterase 4 Inhibitors / pharmacology ; Sarcoplasmic Reticulum Calcium-Transporting ATPases / genetics ; Sarcoplasmic Reticulum Calcium-Transporting ATPases / metabolism ; Ubiquinone / metabolism ; Ubiquinone / pharmacology
  • References: Atherosclerosis. 2001 Nov;159(1):93-101. (PMID: 11689211) ; Cell Metab. 2012 May 2;15(5):739-51. (PMID: 22503562) ; Cell Metab. 2013 Dec 3;18(6):803-15. (PMID: 24268736) ; J Biol Chem. 2007 Jan 5;282(1):194-9. (PMID: 17099248) ; Am J Physiol Endocrinol Metab. 2010 Aug;299(2):E145-61. (PMID: 20371735) ; Antioxid Redox Signal. 2011 Feb 1;14(3):403-13. (PMID: 21091355) ; Microbiol Mol Biol Rev. 2004 Jun;68(2):320-44. (PMID: 15187187) ; Cell. 2012 Feb 3;148(3):421-33. (PMID: 22304913) ; J Lipid Res. 2015 Oct;56(10 ):1985-92. (PMID: 26239051) ; Nat Rev Mol Cell Biol. 2012 Mar 07;13(4):225-238. (PMID: 22395773) ; Endocrinol Jpn. 1970 Feb;17(1):23-35. (PMID: 5468422) ; Arterioscler Thromb Vasc Biol. 2003 Mar 1;23(3):434-9. (PMID: 12615693) ; Cell Calcium. 2002 Nov-Dec;32(5-6):235-49. (PMID: 12543086) ; Proc Natl Acad Sci U S A. 2010 Nov 9;107(45):19320-5. (PMID: 20974941) ; J Agric Food Chem. 2012 Dec 5;60(48):11909-18. (PMID: 23167655) ; Mol Cell. 2011 Dec 23;44(6):851-63. (PMID: 22195961) ; Physiol Rev. 2009 Jul;89(3):1025-78. (PMID: 19584320) ; N Engl J Med. 1984 Dec 13;311(24):1549-58. (PMID: 6390200) ; Nat Rev Endocrinol. 2012 Jan 17;8(5):287-96. (PMID: 22249520) ; Clin J Am Soc Nephrol. 2007 May;2(3):550-62. (PMID: 17699463) ; Eur J Nutr. 2013 Feb;52(1):1-24. (PMID: 22810464) ; Biochem J. 2000 Oct 15;351 Pt 2:289-305. (PMID: 11023813) ; Endocrinology. 2010 Jun;151(6):2747-59. (PMID: 20392834) ; Free Radic Biol Med. 2008 Apr 1;44(7):1259-72. (PMID: 18242193) ; Mutat Res. 2012 May 1;733(1-2):61-8. (PMID: 21964355) ; PLoS One. 2014 Oct 01;9(10):e109223. (PMID: 25272163) ; Free Radic Biol Med. 1999 Nov;27(9-10):1027-32. (PMID: 10569635) ; Lipids. 1989 Jul;24(7):579-84. (PMID: 2779364) ; Biochim Biophys Acta. 1998 May 6;1364(2):207-21. (PMID: 9593895) ; Endocr Rev. 2003 Feb;24(1):78-90. (PMID: 12588810) ; Med Sci Monit. 2011 May;17(5):HY5-9. (PMID: 21525818) ; Nature. 2000 Apr 6;404(6778):635-43. (PMID: 10766250) ; J Urol. 2012 Aug;188(2):526-31. (PMID: 22704112) ; Curr Opin Endocrinol Diabetes Obes. 2010 Oct;17 (5):446-52. (PMID: 20585248) ; Cell Signal. 2012 Dec;24(12):2329-36. (PMID: 22885103) ; J Mol Med (Berl). 2011 Jul;89(7):667-76. (PMID: 21431325) ; J Clin Invest. 1997 Jan 1;99(1):144-50. (PMID: 9011569) ; Adv Physiol Educ. 2006 Dec;30(4):145-51. (PMID: 17108241) ; Cell Metab. 2012 Aug 8;16(2):180-8. (PMID: 22883230) ; Nature. 2009 Apr 23;458(7241):1056-60. (PMID: 19262508) ; Cold Spring Harb Symp Quant Biol. 2007;72:483-8. (PMID: 18419308) ; Nature. 2011 May 26;473(7348):528-31. (PMID: 21532591) ; Science. 2004 Oct 15;306(5695):457-61. (PMID: 15486293) ; Redox Rep. 2013;18(1):12-9. (PMID: 23394493) ; Nature. 2006 Dec 14;444(7121):840-6. (PMID: 17167471) ; Cell Metab. 2008 Oct;8(4):333-41. (PMID: 18840364) ; J Clin Invest. 2004 Dec;114(12):1752-61. (PMID: 15599400) ; Clin Investig. 1993;71(8 Suppl):S66-70. (PMID: 8241708) ; Clin Chim Acta. 2015 Oct 23;450:83-9. (PMID: 26254995) ; Proc Natl Acad Sci U S A. 2009 Nov 17;106(46):19432-7. (PMID: 19901338) ; Hypertension. 2014 Aug;64(2):215-21. (PMID: 24821943) ; Atherosclerosis. 2011 Jul;217(1):158-64. (PMID: 21458815) ; Pharmacol Rev. 2006 Sep;58(3):488-520. (PMID: 16968949) ; Nature. 2004 Jun 17;429(6993):771-6. (PMID: 15175761) ; J Clin Invest. 1993 Jun;91(6):2546-51. (PMID: 8390482) ; Am J Physiol Heart Circ Physiol. 2008 Jul;295(1):H185-96. (PMID: 18487436) ; EMBO J. 2007 Apr 4;26(7):1913-23. (PMID: 17347648) ; Cell. 2006 Dec 15;127(6):1109-22. (PMID: 17112576) ; Ann Intern Med. 1985 Dec;103(6 ( Pt 2)):1010-9. (PMID: 3904565) ; Biochim Biophys Acta. 1991 Dec 10;1072(2-3):129-57. (PMID: 1751545) ; Proc Natl Acad Sci U S A. 2008 Jul 15;105(28):9793-8. (PMID: 18599449) ; Antioxid Redox Signal. 2014 Jun 1;20(16):2606-20. (PMID: 24124769) ; Cardiovasc Res. 2008 Jul 15;79(2):208-17. (PMID: 18430751) ; Obes Surg. 2010 May;20(5):633-9. (PMID: 20033348) ; J Anim Physiol Anim Nutr (Berl). 2008 Jun;92(3):272-83. (PMID: 18477307) ; Cell Metab. 2011 Apr 6;13(4):376-88. (PMID: 21459323) ; Am J Physiol Endocrinol Metab. 2010 Apr;298(4):E751-60. (PMID: 20103737) ; Cell Metab. 2015 Sep 1;22(3):381-97. (PMID: 26190652) ; FEBS Lett. 1987 Nov 2;223(2):217-22. (PMID: 2889619) ; Nat Rev Endocrinol. 2009 Jul;5(7):367-73. (PMID: 19455179)
  • Substance Nomenclature: 0 (Phosphodiesterase 4 Inhibitors) ; 1339-63-5 (Ubiquinone) ; EC 2.7.11.17 (Calcium-Calmodulin-Dependent Protein Kinase Type 2) ; EC 3.1.4.17 (Cyclic Nucleotide Phosphodiesterases, Type 4) ; EC 3.6.3.8 (Sarcoplasmic Reticulum Calcium-Transporting ATPases) ; EJ27X76M46 (coenzyme Q10)
  • Entry Date(s): Date Created: 20170817 Date Completed: 20190315 Latest Revision: 20220316
  • Update Code: 20231215
  • PubMed Central ID: PMC5557856

Klicken Sie ein Format an und speichern Sie dann die Daten oder geben Sie eine Empfänger-Adresse ein und lassen Sie sich per Email zusenden.

oder
oder

Wählen Sie das für Sie passende Zitationsformat und kopieren Sie es dann in die Zwischenablage, lassen es sich per Mail zusenden oder speichern es als PDF-Datei.

oder
oder

Bitte prüfen Sie, ob die Zitation formal korrekt ist, bevor Sie sie in einer Arbeit verwenden. Benutzen Sie gegebenenfalls den "Exportieren"-Dialog, wenn Sie ein Literaturverwaltungsprogramm verwenden und die Zitat-Angaben selbst formatieren wollen.

xs 0 - 576
sm 576 - 768
md 768 - 992
lg 992 - 1200
xl 1200 - 1366
xxl 1366 -